世界の脊髄性筋萎縮症（SMA）治療薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Spinal Muscular Atrophy (SMA) Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A11910 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、70ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、脊髄性筋萎縮症（SMA）治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。脊髄性筋萎縮症（SMA）治療薬の種類別市場規模（内服薬、注射薬）、用途別市場規模（赤ちゃん、子供、大人）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・脊髄性筋萎縮症（SMA）治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Biogen、Novartis、Genentech ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：内服薬、注射薬 ・用途別分析2016年-2026年：赤ちゃん、子供、大人 ・脊髄性筋萎縮症（SMA）治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・脊髄性筋萎縮症（SMA）治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・脊髄性筋萎縮症（SMA）治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・脊髄性筋萎縮症（SMA）治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・脊髄性筋萎縮症（SMA）治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Spinal Muscular Atrophy (SMA) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Spinal Muscular Atrophy (SMA) Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Spinal Muscular Atrophy (SMA) Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Spinal Muscular Atrophy (SMA) Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Oral Medicine
Injection Medicine

Market segment by Application, can be divided into
Baby
Child
Adult

Market segment by players, this report covers
Biogen
Novartis
Genentech

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Spinal Muscular Atrophy (SMA) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Spinal Muscular Atrophy (SMA) Drugs, with revenue, gross margin and global market share of Spinal Muscular Atrophy (SMA) Drugs from 2019 to 2021.
Chapter 3, the Spinal Muscular Atrophy (SMA) Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Spinal Muscular Atrophy (SMA) Drugs market forecast, by regions, type and end user, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Spinal Muscular Atrophy (SMA) Drugs research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Spinal Muscular Atrophy (SMA) Drugs
1.2 Classification of Spinal Muscular Atrophy (SMA) Drugs by Type
1.2.1 Overview: Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type in 2020
1.2.3 Oral Medicine
1.2.4 Injection Medicine
1.3 Global Spinal Muscular Atrophy (SMA) Drugs Market by End User
1.3.1 Overview: Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Baby
1.3.3 Child
1.3.4 Adult
1.4 Global Spinal Muscular Atrophy (SMA) Drugs Market Size & Forecast
1.5 Global Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast by Region
1.5.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region, (2016-2021)
1.5.3 North America Spinal Muscular Atrophy (SMA) Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Spinal Muscular Atrophy (SMA) Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Spinal Muscular Atrophy (SMA) Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Spinal Muscular Atrophy (SMA) Drugs Market Drivers
1.6.2 Spinal Muscular Atrophy (SMA) Drugs Market Restraints
1.6.3 Spinal Muscular Atrophy (SMA) Drugs Trends Analysis
2 Company Profiles
2.1 Biogen
2.1.1 Biogen Details
2.1.2 Biogen Major Business
2.1.3 Biogen Spinal Muscular Atrophy (SMA) Drugs Product and Solutions
2.1.4 Biogen Spinal Muscular Atrophy (SMA) Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Biogen Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Spinal Muscular Atrophy (SMA) Drugs Product and Solutions
2.2.4 Novartis Spinal Muscular Atrophy (SMA) Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Genentech
2.3.1 Genentech Details
2.3.2 Genentech Major Business
2.3.3 Genentech Spinal Muscular Atrophy (SMA) Drugs Product and Solutions
2.3.4 Genentech Spinal Muscular Atrophy (SMA) Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Genentech Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Spinal Muscular Atrophy (SMA) Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Spinal Muscular Atrophy (SMA) Drugs Players Market Share
3.2.2 Top 10 Spinal Muscular Atrophy (SMA) Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Spinal Muscular Atrophy (SMA) Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Spinal Muscular Atrophy (SMA) Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Spinal Muscular Atrophy (SMA) Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Application (2016-2021)
5.2 Spinal Muscular Atrophy (SMA) Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2026)
6.2 North America Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2026)
6.3 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country
6.3.1 North America Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2016-2026)
6.3.2 United States Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2026)
7.2 Europe Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2026)
7.3 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country
7.3.1 Europe Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2016-2026)
7.3.2 Germany Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
7.3.3 France Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region
8.3.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue by Region (2016-2026)
8.3.2 China Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
8.3.5 India Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2026)
9.2 South America Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2026)
9.3 South America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country
9.3.1 South America Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country
10.3.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Spinal Muscular Atrophy (SMA) Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Spinal Muscular Atrophy (SMA) Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Region (2021-2026)
Table 6. Biogen Corporate Information, Head Office, and Major Competitors
Table 7. Biogen Major Business
Table 8. Biogen Spinal Muscular Atrophy (SMA) Drugs Product and Solutions
Table 9. Biogen Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Novartis Corporate Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Spinal Muscular Atrophy (SMA) Drugs Product and Solutions
Table 13. Novartis Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Genentech Corporate Information, Head Office, and Major Competitors
Table 15. Genentech Major Business
Table 16. Genentech Spinal Muscular Atrophy (SMA) Drugs Product and Solutions
Table 17. Genentech Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Global Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million) by Players (2019-2021)
Table 19. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Share by Players (2019-2021)
Table 20. Breakdown of Spinal Muscular Atrophy (SMA) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 21. Spinal Muscular Atrophy (SMA) Drugs Players Head Office, Products and Services Provided
Table 22. Spinal Muscular Atrophy (SMA) Drugs Mergers & Acquisitions in the Past Five Years
Table 23. Spinal Muscular Atrophy (SMA) Drugs New Entrants and Expansion Plans
Table 24. Global Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million) by Type (2016-2021)
Table 25. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Share by Type (2016-2021)
Table 26. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Forecast by Type (2021-2026)
Table 27. Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2021)
Table 28. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Forecast by Application (2021-2026)
Table 29. North America Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2021) & (USD Million)
Table 30. North America Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2021-2026) & (USD Million)
Table 31. North America Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2021) & (USD Million)
Table 32. North America Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2021-2026) & (USD Million)
Table 33. North America Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2016-2021) & (USD Million)
Table 34. North America Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2021-2026) & (USD Million)
Table 35. Europe Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2021) & (USD Million)
Table 36. Europe Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2021-2026) & (USD Million)
Table 37. Europe Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2021) & (USD Million)
Table 38. Europe Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2021-2026) & (USD Million)
Table 39. Europe Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2016-2021) & (USD Million)
Table 40. Europe Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2021-2026) & (USD Million)
Table 41. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2021) & (USD Million)
Table 42. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2021-2026) & (USD Million)
Table 43. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2021) & (USD Million)
Table 44. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2021-2026) & (USD Million)
Table 45. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue by Region (2016-2021) & (USD Million)
Table 46. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue by Region (2021-2026) & (USD Million)
Table 47. South America Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2021) & (USD Million)
Table 48. South America Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2021-2026) & (USD Million)
Table 49. South America Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2021) & (USD Million)
Table 50. South America Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2021-2026) & (USD Million)
Table 51. South America Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2016-2021) & (USD Million)
Table 52. South America Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2021-2026) & (USD Million)
Table 53. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2016-2021) & (USD Million)
Table 54. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue by Type (2021-2026) & (USD Million)
Table 55. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2016-2021) & (USD Million)
Table 56. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue by Application (2021-2026) & (USD Million)
Table 57. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2016-2021) & (USD Million)
Table 58. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Spinal Muscular Atrophy (SMA) Drugs Picture
Figure 2. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type in 2020
Figure 3. Oral Medicine
Figure 4. Injection Medicine
Figure 5. Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by End User in 2020
Figure 6. Baby Picture
Figure 7. Child Picture
Figure 8. Adult Picture
Figure 9. Global Spinal Muscular Atrophy (SMA) Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Spinal Muscular Atrophy (SMA) Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Region (2016-2026)
Figure 12. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Region in 2020
Figure 13. North America Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Spinal Muscular Atrophy (SMA) Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Spinal Muscular Atrophy (SMA) Drugs Market Drivers
Figure 19. Spinal Muscular Atrophy (SMA) Drugs Market Restraints
Figure 20. Spinal Muscular Atrophy (SMA) Drugs Market Trends
Figure 21. Biogen Recent Developments and Future Plans
Figure 22. Novartis Recent Developments and Future Plans
Figure 23. Genentech Recent Developments and Future Plans
Figure 24. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Share by Players in 2020
Figure 25. Spinal Muscular Atrophy (SMA) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 26. Global Top 3 Players Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share in 2020
Figure 27. Global Top 10 Players Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share in 2020
Figure 28. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 29. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Share by Type in 2020
Figure 30. Global Spinal Muscular Atrophy (SMA) Drugs Market Share Forecast by Type (2021-2026)
Figure 31. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Share by Application in 2020
Figure 32. Global Spinal Muscular Atrophy (SMA) Drugs Market Share Forecast by Application (2021-2026)
Figure 33. North America Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Type (2016-2026)
Figure 34. North America Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Application (2016-2026)
Figure 35. North America Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Country (2016-2026)
Figure 36. United States Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 37. Canada Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 38. Mexico Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 39. Europe Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Type (2016-2026)
Figure 40. Europe Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Application (2016-2026)
Figure 41. Europe Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Country (2016-2026)
Figure 42. Germany Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. France Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. United Kingdom Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Russia Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Italy Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Type (2016-2026)
Figure 48. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Application (2016-2026)
Figure 49. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Region (2016-2026)
Figure 50. China Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Japan Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. South Korea Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. India Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Australia Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. South America Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Type (2016-2026)
Figure 57. South America Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Application (2016-2026)
Figure 58. South America Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Country (2016-2026)
Figure 59. Brazil Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Argentina Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Middle East and Africa Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Type (2016-2026)
Figure 62. Middle East and Africa Spinal Muscular Atrophy (SMA) Drugs Sales Market Share by Application (2016-2026)
Figure 63. Middle East and Africa Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Country (2016-2026)
Figure 64. Turkey Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. UAE Spinal Muscular Atrophy (SMA) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Methodology
Figure 68. Research Process and Data Source

---